Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. (Q35567931)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

main subject

phase II clinical trial

0 references

0 references

1 reference

1 reference

Gilberto Schwartsmann

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Lissandra Dal Lago

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Marc F Richter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Anna I Cancela

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Sabrina A Fernandes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Keylla T Jung

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Ana C Rodrigues

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Teresa Dalla Costa

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Luciane P Di Leone

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 August 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

359-366

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14578685%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1025485031112

20 December 2019

exact match

0 references

cites work

Pharmacokinetics of thalidomide in an elderly prostate cancer population

1 reference

12 December 2020

Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers.

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations

1 reference

12 December 2020

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

1 reference

12 December 2020

Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis

1 reference

12 December 2020

Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis.

1 reference

12 December 2020

Irinotecan/thalidomide in metastatic colorectal cancer.

1 reference

12 December 2020

Thalidomide is an inhibitor of angiogenesis

1 reference

12 December 2020

Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

Tumor angiogenesis: therapeutic implications

1 reference

12 December 2020

Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study

1 reference

12 December 2020

Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation

1 reference

12 December 2020

Tumor angiogenesis and mode of metastasis in patients with colorectal cancer

1 reference

12 December 2020

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor

1 reference

12 December 2020

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

12 December 2020

Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug

1 reference

12 December 2020

Irinotecan and thalidomide in metastatic colorectal cancer

1 reference

12 December 2020

The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study

1 reference

12 December 2020

Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers

1 reference

12 December 2020

Malformations Caused by Drugs in Pregnancy

1 reference

12 December 2020

THALIDOMIDE (N-PHTHALOYLGLUTAMIMIDE) IN THE TREATMENT OF ADVANCED CANCER.

1 reference

12 December 2020

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

12 December 2020

Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s?

1 reference

12 December 2020